Abstract: Phospholipases A 2 (PLA 2 s) are enzymes that are capable of catalyzing the hydrolysis of the sn-2 ester bond of glycerophospholipids, releasing free fatty acids, including arachidonic acid (AA), and lysophospholipids. Both products are precursor signaling molecules involved in inflammation. Among the various PLA 2 s, cytosolic GIVA cPLA 2 is considered a major target for inflammatory diseases, while secreted GIIA sPLA 2 is involved in cardiovascular diseases. We have developed lipophilic 2-oxoamides based on (S)-γ-or δ-amino acids as potent and selective inhibitors of GIVA cPLA 2 , which present interesting in vivo anti-inflammatory activity. 2-Oxoamides based on natural α-amino acids are selective inhibitors of GIIA sPLA 2 . The mode of binding of 2-oxoamides with either GIVA cPLA 2 or GIIA sPLA 2 has been studied by various techniques.
INTRODUCTION
Phospholipases A 2 (PLA 2 s) constitute one of the largest families of lipolytic enzymes defined by their ability to catalyze the hydrolysis of the ester bond at the sn-2 position of glycerophospholipids, yielding free fatty acids and lysophospholipids [1] . Free fatty acids released, mainly arachidonic acid (AA), may be metabolized to form various eicosanoids and related bioactive proinflammatory lipids [2] . Hence, inhibiting AA release is of great relevance for the development of new anti-inflammatory drugs. Lysophospholipids also have various important roles in biological processes [3] . The PLA 2 super family currently consists of 15 groups and many subgroups, which differ in primary sequence, structure, and catalytic mechanism [1] . There are four predominant types of PLA 2 : the secreted PLA 2 (sPLA 2 ), the cytosolic Ca 2+ -dependent PLA 2 (cPLA 2 ), the cytosolic Ca 2+ -independent PLA 2 (iPLA 2 ), and the lipoprotein-associated PLA 2 (LpPLA 2 ). Each of them plays key roles in cells and organisms being involved in diverse kinds of lipid biology and producing a variety of bioactive lipids. Potent and selective inhibitors of lipolytic enzymes could help to shed light on their physiological functions and associated metabolic pathways [4] . This is the reason for tremendous interest in discovering PLA 2 inhibitors as novel potential therapeutic agents of inflammatory diseases.
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The various classes of intracellular and extracellular PLA 2 inhibitors have been summarized in recent review articles [1, [5] [6] [7] [8] . Among them, varespladib methyl ( Fig. 1) , a human GIIA sPLA 2 inhibitor, was entered into clinical trials for the treatment of severe sepsis. However, the trials terminated at phase II because the results were not robust. Years later, Anthera Pharmaceuticals pursued the same inhibitor for the treatment of cardiovascular diseases, which is currently in phase III trials. Concerning GIVA cPLA 2 , giripladib ( Fig. 1 ) was advanced into a phase II clinical trial for osteoarthritis, but the trial was terminated owing to a failure to differentiate from the standard of care with naproxen because of gastroenterologic effects.
Our laboratory has developed a new class of inhibitors of PLA 2 , containing the 2-oxoamide functionality, which have been studied for their activity and selectivity on three human PLA 2 classes: GIVA cPLA 2 , GVIA iPLA 2 and GV sPLA 2 . To understand the role and specificity of 2-oxoamide inhibitors, experiments in cells and in vivo have also been performed. This review article summarizes synthetic methods for the preparation of 2-oxoamides, in vitro and in vivo activities of 2-oxoamides and studies on their mode of interaction with GIVA cPLA 2 and GIIA sPLA 2 .
PHOSPHOLIPASE A 2 ENZYMES
Cytosolic phospholipase A 2 The cytosolic PLA 2 s are large proteins with variable sizes (61-114 kDa). Groups IVA, IVB, IVC, IVD, IVE, and IVF are included in this category. The first group IVA cytosolic enzyme was identified in human platelets and was cloned and sequenced in 1991 [9, 10] . The most well characterized enzyme of this category is GIVA cPLA 2 , which selectively releases AA from the sn-2 position of phospholipids. This enzyme also possesses lysophospholipase and transacylase activity.
The properties of the group IVA PLA 2 have been reviewed [11] . The structure of GIVA cPLA 2 shows that it is composed of a Ca 2+ -dependent lipid binding C2 domain and a catalytic α/β hydrolase domain [12] . The catalytic domain is composed of a core α/β hydrolase region, a typical motif for many different lipases, as well as a cap region. Ca 2+ binding in this enzyme is not required for catalysis, as in the secreted sPLA 2 enzymes, but for translocation to the membrane surface. The enzyme possesses an unusual Ser-Asp catalytic dyad located in a deep cleft at the center of a hydrophobic funnel. The catalytic mechanism of GIVA cPLA 2 proceeds through a serine-acyl intermediate using Ser-228 as the nucleophilic residue [13, 14] . [15] . Six different types, GVIA, GVIB, GVIC, GVID, GVIE, and GVIF, are included in this category. GVIA iPLA 2 was purified from macrophages in 1994 [16] and is the best characterized enzyme of this category. The GVIA iPLA 2 enzyme contains a consensus lipase motif, Gly-Thr-Ser*-Thr-Gly, with the catalytic serine confirmed by site-directed mutagenesis [17] .
Although it shares the same catalytic mechanism with GIVA PLA 2 , it does not show specificity for AA at the sn-2 position of phospholipids.
Secreted phospholipase A 2
The sPLA 2 s were the first type of PLA 2 enzymes discovered. PLA 2 was known to be a major component of snake venoms from the end of the 19 th century, and it was recognized as a component of pancreatic juice. sPLA 2 s from various sources belong to groups IA, IB, IIA, IIB, IIC, IID, IIE, IIF, III, V, IX, X, XIA, XIB, XII, XIII, and XIV [1] . GIIA PLA 2 was found in high concentrations in synovial fluid from patients suffering from rheumatoid arthritis [18] . Thus, great attention was initially focused on mammalian GIIA sPLA 2 in the sense that it plays an important role in inflammation. Later, it was reported that various secreted PLA 2 enzymes are expressed in rheumatoid arthritis and augment prostaglandin production in cultured synovial cells [19] . The sPLA 2 s are small secreted proteins (14-18 kDa) usually containing five to eight disulfide bonds. They require millimolar concentrations of Ca 2+ for hydrolysis of phospholipids and do not exhibit preference for specific fatty acids at the sn-2 position of the substrate. This group of enzymes utilizes an active-site histidine together with an aspartate residue for the catalytic mechanism. Many of the sPLA 2 s share the property of exhibiting an increase in activity when the substrate is presented as a large lipid aggregate, rather than a monomeric form, a phenomenon called "interfacial activation" [20] .
Lipoprotein-associated phospholipase A 2
Several secreted and intracellular platelet-activating factor (PAF) acetylhydrolases have been identified [1] . Plasma PAF-acetylhydrolase (PAF-AH), also known as lipoprotein-associated phospholipase A 2 (LpPLA 2 ), catalyzes the hydrolysis, and therefore the inactivation, of PAF and certain oxidized phospholipids. Owing to its PLA 2 catalytic activity, it has been classified as GVIIA PLA 2 [1] . The plasma enzyme is tightly bound to low-and high-density lipoprotein particles and therefore acts on the lipid-aqueous interface and can be considered as a peripheral membrane protein. The PAF-AH crystal structure has been very recently resolved [21] . The enzyme has a typical lipase α/β hydrolase fold, with a Ser273/His351/Asp296 catalytic triad in its active site. Catalytic Ser273 is located at the N-terminus of an α-helix, within the typical GXSXG sequence found in other lipases. The amide nitrogen atoms of Phe274 and Leu153 stabilize the negative charge of the hydrolysis reaction tetrahedral intermediate, and these residues act as an oxyanion hole.
Biological function and involvement of PLA 2 s in diseases
GIVA cPLA 2 is generally considered to be a central enzyme mediating generation of multiple lipid mediators, including eicosanoids and potentiating pain and inflammation. Thus, it plays a major role in inflammatory diseases. GIVA cPLA 2 deficiency in patients and knockout mice models has shown decreased eicosanoid production and mitigation in the effects of inflammatory diseases. These mice showed significant decrease in allergic response, damage from acute lung injury and postischemic brain injury [22−26] . Notable defects caused by the loss of GIVA cPLA 2 are found in the female knockout mice reproduction system [25] . Most recently, the role of GIVA cPLA 2 in prostate cancer [27] and Alzheimer's disease [28] has been proposed, and the application of cPLA 2 inhibitors for the prevention and treatment of these diseases has been discussed. Recent review articles discuss the role of GVIA iPLA 2 in signaling and pathological conditions, for example, cancer and ischemia [29−32] . GVIA iPLA 2 has been proposed to be a homeostatic enzyme involved in basal metabolism inside the cell. However, a number of studies suggest that GVIA iPLA 2 plays important though different roles in numerous cell types. It has been reported that iPLA 2 participates in ER stress-induced apoptosis, a pathway that promotes β-cell death in diabetes [33] . It was also demonstrated that iPLA 2 -null male mice produce spermatozoa with impaired motility and have greatly reduced fertility [34] . In addition, the absence of iPLA 2 causes abnormalities in osteoblast function and bone marrow stromal cells differentiation, indicating the role of iPLA 2 in bone formation [35] .
The biochemistry and physiology of mammalian sPLA 2 s have been reviewed [36−38] . Numerous in vitro studies document the ability of GV and GX sPLA 2 , and to a lesser extent GIIA sPLA 2 , to generate AA for eicosanoid production in inflammatory cells, including macrophages, neutrophils, eosinophils, and mast cells [36] . In some cases, the activity of sPLA 2 has been shown to be dependent on or linked to the activity of GIVA cPLA 2 . The sPLA 2 s appear to play a role in several inflammatory diseases. The first evidence was that GIIA sPLA 2 was present at high concentrations in the synovial fluid from arthritic knee joints [18] . GIIA sPLA 2 -deficient mice have shown reduced signs of arthritis when compared with wild-type mice. Accumulating evidence has indicated that at least three sPLA 2 s, GIIA, GV, and GX, exert multiple proatherogenic properties in the vessel wall [39−45] . A recent article by Gelb et al. provides clear evidence that GX sPLA 2 is a novel therapeutic target for asthma [46] .
2-OXOAMIDES: SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIP STUDIES

2-Oxoamide inhibitors of cytosolic phospholipase A 2
Design of 2-oxoamide inhibitors of GIVA cPLA 2 Novel inhibitors were initially designed taking into consideration the enzyme's catalytic mechanism and the structure of the substrate [47, 48] . The catalytic mechanism of GIVA cPLA 2 proceeds through a serine-acyl intermediate after attack of the nucleophilic Ser-228. Our strategy for the design of novel GIVA cPLA 2 inhibitors was based on the principle that the inhibitor should consist of several parts: (a) an electrophilic functionality, such as an activated carbonyl group that may interact with the active-site serine, (b) a lipophilic segment, and (c) the appropriate chemical motifs necessary for specific interactions and proper orientation in the enzyme's active site (Fig. 2 ).
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Synthesis of 2-oxoamide inhibitors based on natural and non-natural amino acids
According to the initial design, first-generation 2-oxoamides inhibitors synthesized by the Kokotos group, were based on γ-amino acid residues, such as γ-aminobutyric acid and γ-norleucine [47−50] . Therefore, three routes were developed for their synthesis, depending on the C-protecting group of the ylide and the N-protecting group used (Scheme 1). Wittig reactions of Boc-protected amino aldehydes 2 with benzyl or methyl (triphenylphosphoranylidene)acetate led to α,β-unsaturated esters 3 and 4. The Boc group was removed, and the amino component was coupled with 2-hydroxyalkanoic acid. Catalytic hydrogenation and saponification, followed by oxidation led to the target compounds 9. The Z-protected amino aldehydes 2 were treated with tert-butyl (triphenylphosphoranylidene)-acetate, to give compounds 5. After catalytic hydrogenation, the amino component was coupled with 2-hydroxyalkanoic acid. Oxidation of the latter, followed by the removal of the tert-butyl group, led to the desired products 9.
Another synthetic approach for the preparation of the 2-oxoamide functionality has been applied via direct coupling reaction between labile α,β-diketo-nitriles 11 and γ-aminobutyric acid tert-butyl ester derivatives, as depicted in Scheme 1 [51] .
To obtain β-and δ-norleucine-based inhibitors 16 and 19, the oxidative conversion of a phenyl group to a carboxylic acid was the key reaction, as shown in Scheme 2. Amino components may be prepared via a Wittig-type olefination reaction of a Boc-protected aminoaldehyde with the suitable ylide [52, 53] . Alcohols 13 and 1 were used as starting materials.
For the synthesis of the ε-norleucine-based inhibitors 22, the Boc-protected norleucinol 1 was oxidized to the aldehyde and directly reacted with triethyl phosphonocrotonate (Scheme 3). Catalytic hydrogenation of 20, removal of the Boc group, and coupling with 2-hydroxy acids produced the corresponding 2-hydroxyamides 21. Saponification, followed by oxidation, led to the desired inhibitors 22 [50, 52] . To obtain α-through δ-amino acid-based 2-oxoamide derivatives without any side chain, 2-hydroxy acids were coupled with glycine, β-alanine, γ-aminobutyric, and δ-aminovaleric acid esters [48] [49] [50] . In all the above-mentioned cases, to obtain the corresponding ester derivatives, oxidation of the 2-hydroxy-amide moiety took place without deprotection of the carboxyl group. duce AA, which subsequently can be converted to prostaglandin E 2 (PGE 2 ). AA can also be used to upregulate the message and protein levels of GV PLA 2 , which in turn produces its own AA that goes on to form PGE 2 . Both AX006 and AX007 were able to completely block PGE 2 release with the addition of 50 μM inhibitor, and neither of them showed cytotoxicity at this dose. The IC 50 values for the inhibition of PGE 2 release were 7.8 μM for AX006 and 5.8 μM for AX007 [48] . To evaluate the antiinflammatory activity of 2-oxoamide inhibitors, the rat paw carrageenan-induced edema assay was employed as a model for acute inflammation. Indomethacin was used in these experiments as a reference drug and gave 47 % inhibition of inflammation at a dose of 0.01 mmol/kg. AX006 and AX012 exhibited in vivo anti-inflammatory activity comparable to that of indomethacin, whereas AX007 exhibited a weaker effect [48] .
To further elucidate the structure-activity relationships, additional 2-oxoamide derivatives based on α-through ε-amino acids, were synthesized and tested for their ability to inhibit GIVA cPLA 2 (Fig. 4) . Compounds AX040 and AX074, based on γ-aminobutyric acid and α,β-unsaturated γ-norleucine, bearing an oleyl-like and a tetradecanyl chain, strongly inhibited GIVA cPLA 2 , with X I (50) values of 0.011 and 0.003 mol fraction. The latter is the most potent in vitro 2-oxoamide inhibitor of GIVA cPLA 2 reported to date [49] . A δ-amino acid derivative, (S)-5-(2-oxohexadecanamido)nonanoic acid (AX109, Fig. 4 ) proved also to be a very potent GIVA cPLA 2 inhibitor, with a X I (50) value of 0.005, presenting anti-inflammatory activity at very low doses [52] .
2-Oxoamide AX059, based on γ-leucine, is also a potent and selective inhibitor of GIVA cPLA 2 with a X I (50) value of 0.008 mol fraction (Fig. 5 ). Mice treated with AX059 showed a significant reduction in the severity of the early course of the experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis [54] . Moreover, it prevented the hydrolysis of all fatty acids from phospholipids that were increased in EAE, and the production of PGE 2 , thromboxane B2 (TXB2), and other proinflammatory agents [54] . In contrast to neuroinflammatory conditions, such as EAE, mice treated with AX059 showed greater locomotor deficits and tissue loss after spinal cord injury (SCI) [55] . It was found that GIVA cPLA 2 was expressed in neurons and oligodendrocytes in the spinal cord after injury, and cPLA 2 -null mice and wild-type mice treated with AX059 displayed greater neuronal and myelin loss after injury, suggesting that inhibition or deletion of cPLA 2 make these cells more vulnerable. Thus, contrary to other models of CNS disorders in which cPLA 2 seems to contribute to tissue damage [23,56−58] , our very recent data indicated a protective role for cPLA 2 after SCI [55] . The ethyl ester variant of compound AX006, AX048 (Fig. 3) , inhibits both GIVA cPLA 2 and GVIA iPLA 2 to almost the same extent [59] . Very interestingly, it exerted a significant effect upon centrally and peripherally initiated hyperalgesia in rats, induced by spinally delivered substance P and carrageenan (Fig. 6) . The selective in vitro GIVA cPLA 2 inhibitor AX006 did not seem to get access to the intracellular PLA 2 . This fact maybe indicates that this molecule's properties allow penetration of cellular membranes and it maybe acts as a prodrug of AX006 [59] .
Design and synthesis of 2-oxoamide inhibitors based on dipeptides/pseudodipeptides To extend our studies on the inhibition of PLA 2 s by 2-oxoamides, a variety of 2-oxoamides based on dipeptides and pseudodipeptides were synthesized and their in vitro activity on three human PLA 2 classes: GIVA cPLA 2 , GVIA iPLA 2 , and GV sPLA 2 were studied [60] . Dipeptides are considered to be δ-amino acid analogs, because of the distance between the N-and C-terminal groups. Ether pseudo - peptide derivatives may be also considered δ-amino acid derivatives. Thus, L-norleucine and L-valine were chosen as starting materials to synthesize a series of derivatives that contain the 2-oxoamide functionality and an amide group or ether group to replace the two methylenes of the δ-amino acid derivative (Fig. 7) . For the synthesis of 2-oxoamide derivatives based on dipeptides, N-protected amino acids 23 were coupled with methyl, ethyl or tert-butyl glycinate (Scheme 4). Removal of the protecting group, followed by coupling with 2-hydroxyhexadecanoic acid yielded the 2-hydroxyamides 25. Oxidation of the latter led to the target compounds 26. Following similar reactions, tert-butyl ester derivatives were prepared as depicted in Scheme 4, starting from Z-protected amino acids. For the synthesis of pseudodipeptide derivatives, the key reaction step was the treatment of N-protected norleucinol with ethyl or tert-butyl bromoacetate to give ether derivatives 28 (Scheme 4). The corresponding free carboxylic acid compounds 27 and 31 were obtained after removal of the tert-butyl ester group of 26 and 30 [60] .
Inhibition of cPLA 2 by dipeptide-and pseudodipeptide-based 2-oxoamides 2-Oxoamide derivatives based on dipeptides Nle-Gly and Val-Gly (27, Scheme 4), bearing a free carboxylic acid, were moderate, though selective inhibitors of GIVA cPLA 2 . The bioisosteric replacement of the Nle-Gly derivative amide bond with an ether moiety (31, Scheme 4), led to significantly higher inhibition of [X I (50) 0.017]. Very interestingly, 2-oxoamides ester variants 26 based on Nle-Gly-OMe and Val-Gly-OBu t , showed a higher inhibition potency in comparison with the corresponding free acid derivatives. However, both inhibited GVIA iPLA 2 as well. Moreover, selective GIVA cPLA 2 inhibitors blocked AA release in RAW 264.7 macrophages. Particularly, ether pseudodipeptide derivative 31 inhibited AA release with an IC 50 value of 2 μM, whereas under the same conditions, the most potent in vitro inhibitors of GIVA cPLA 2 AX074, and AX109 had IC 50 values of 25 and 7 μM, respectively [60] .
2-Oxoamide inhibitors containing carboxylate bioisosteric groups
A variety of lipophilic 2-oxoamides containing sulfonamide groups bioisosteric to the carboxyl group, as analogs of γ-and δ-amino acids, as well as acyl sulfonamides of γ-aminobutyric acid were synthesized (Fig. 8) , and their activity on three human PLA 2 classes was evaluated [61] . Three of them inhibited GIVA cPLA 2 at a level similar to that of the lead compounds AX006 and AX048. Thus, the bioisosteric sulfonamide group seems a group suitable to replace the carboxyl group in lipophilic 2-oxoamide inhibitors of GIVA cPLA 2 .
Other bioisosteric analogs synthesized and tested were based on the replacement of the carboxyl or the carboxyl ester group of AX006 and AX048 by a tetrazole or phosphonate group (Fig. 8 ) [62] . All compounds of this category proved to be weak inhibitors of GIVA cPLA 2 .
2-Oxoamide inhibitors of Ca 2+ -independent phospholipase A 2
To understand the selectivity of 2-oxoamides toward each type of PLA 2 s, all 2-oxoamide derivatives were tested for their ability to inhibit the three classes of PLA 2 . As mentioned above, GVIA iPLA 2 shares the same catalytic mechanism with GIVA cPLA 2 . Thus, it is very likely that inhibitors of GIVA cPLA 2 may show cross-reactivity with GVIA iPLA 2 . Natural and non-natural amino acid-based 2-oxoamide inhibitors The first observation that occurred from inhibition studies was that derivatives with a free carboxylic acid functionality do not inhibit GVIA iPLA 2 . On the other hand, corresponding esters may inhibit both GIVA cPLA 2 and GVIA iPLA 2 . More specifically, uncharged variants of AX040 and AX074, namely, AX041 and AX073 (Fig. 4) , showed high activity against both cytosolic enzymes, with preference for GIVA cPLA 2 [49] . As previously noted, 2-oxoamide AX048, based on ethyl γ-aminobutyrate, inhibited both GIVA cPLA 2 and GVIA iPLA 2 and exhibited very interesting antihyperalgesic activity [59] . Other 2-oxoamide esters with varying distance between the 2-oxoamide functionality and the ester group (one to five carbon atoms) and varying amino acid side chain, presented moderate inhibition of GVIA iPLA 2 at 0.091 mol fraction, and none of them was selective for this enzyme [50] .
Dipeptide-and pseudodipeptide-based 2-oxoamide inhibitors As mentioned above, 2-oxoamides based on dipeptides and ether pseudodipeptides were tested also for their ability to inhibit GVIA iPLA 2 . Two interesting inhibitors were identified, based on Nle-Gly tertbutyl ester 26, and the ether pseudodipeptide ethyl ester 30 (Fig. 9) . Up to now, these are the most effective in vitro 2-oxoamides that preferentially inhibit GVIA iPLA 2 [60] .
The results of GIVA cPLA 2 and GVIA iPLA 2 inhibition caused by some 2-oxoamides are summarized in Table 1 . Initially, the percent inhibition of each PLA 2 at 0.091 mol fraction of inhibitor was determined. X I (50) values were estimated when the percent inhibition was higher than 90 %. The X I (50) is the mol fraction of the inhibitor in the total substrate interface required to inhibit the enzyme by 50 %. 
2-Oxoamide inhibitors of secreted phospholipase A 2
Although there is no serine nucleophile in sPLA 2 s, 2-oxoamides may resemble the substrate phospholipids or the transition state in such way that they would bind to the sPLA 2 s active site and inhibit the enzyme.
Amino acid-based 2-oxoamide inhibitors Numerous 2-oxoamides based on α-through ε-amino acids with varying side chains were tested for their ability to cause inhibition of GV sPLA 2 . In general, derivatives with a free carboxylic acid group, that are potent inhibitors of GIVA cPLA 2 , poorly inhibit GV sPLA 2 , or cause no inhibition at all [52, 60] . The glutamic acid derivative 36 ( Fig. 10) Most recently, 2-oxoamide derivatives based on α-amino acids have been synthesized and tested for their in vitro inhibitory activity against three human sPLA 2 s (GIIA, GV, and GX) [63] . Compound GK126 (Fig. 10) , which is based on (S)-leucine, displayed inhibition of human and mouse GIIA sPLA 2 (IC 50 300 and 180 nM, respectively). It also inhibited the human GV sPLA 2 with similar potency, while it did not display any measurable inhibition of GX sPLA 2 .
STUDIES ON THE MODE OF BINDING OF 2-OXOAMIDES WITH PLA 2 s
The identification of new PLA 2 inhibitors can be assisted by the so-called computer-aided drug design (CADD). Through several approaches, including ligand-based design, structure-based design, and quantitative structure-activity relationships, researches apply computational techniques in an effort to streamline the discovery, design, development, and optimization of inhibitors against a target receptor. The application of rational design on the PLA 2 enzymes area and specifically the contribution of CADD in the identification of new PLA 2 inhibitors has been recently reviewed [64] .
Binding of 2-oxoamides with GIVA cPLA 2 A detailed analysis of the binding mode of two potent, but structurally different GIVA cPLA 2 inhibitors, namely, pyrrophenone and the 2-oxoamide AX007, has been conducted using for the first time a combination of deuterium exchange mass spectrometry (DXMS) and molecular dynamics (MD) simulations [65] . This study allowed key residues contacting both inhibitors to be modeled. It was found that the carboxylic acid moiety of AX007 interacted with Arg200, as postulated in the initial design, and the carbonyl group of the 2-oxoamide functionality was in contact with the oxyanion hole composed of the residues Gly197 and Gly198 (Fig. 11) . It was also observed that the 2-oxoamide mainly occupied the active-site area, while the inhibitor pyrrophenone was bound in the cap region near the interfacial surface of the enzyme. This methodology certainly provides a new exciting tool to develop inhibitors with improved properties. Binding of 2-oxoamides with GIIA sPLA 2 Assisted by molecular docking studies, it was possible to understand the structural characteristics that contribute to the inhibitory activity of the 2-oxoamide GK126 against GIIA sPLA 2 [63] . The 2-oxoamide group is essential for the binding because it participates in hydrogen bonds with Gly29 and interacts with the calcium ion. The carboxylate group is also essential for binding because it interacts with the calcium ion and participates in a hydrogen bond with Lys62 through a water molecule placed near the hydrophilic region of the active site. The (S)-leucine side chain contributes to the tight binding of GK126 by interacting with the side chain of the active-site Leu2 (Fig. 12 ). Location of inhibitor AX007 bound to cPLA 2 determined by DEMS and MD [65] .
Fig. 12
The binding mode of the inhibitor GK126 in the GIIA sPLA 2 active site as calculated using GOLD [63] .
CONCLUSIONS
PLA 2 has been widely recognized as a target for the development of novel anti-inflammatory medicinal agents. Although the area of research on PLA 2 inhibitors has been very active during the last decade, no inhibitor has reached the market. 2-Oxoamides constitute one of the promising classes of PLA 2 inhibitors. Lipophilic 2-oxoamides based on (S)-γ-or δ-amino acids are potent and selective inhibitors of GIVA cPLA 2 , which present interesting in vivo anti-inflammatory activity. However, 2-oxoamides based on natural α-amino acids are selective inhibitors of GIIA sPLA 2 (Fig. 13) .
The application of various techniques unraveled the mode of binding of 2-oxoamides with the cytosolic GIVA cPLA 2 and the secreted GIIA sPLA 2 . Further modifications on the 2-oxoamide structure are expected to lead to new improved inhibitors with therapeutic potential.
